Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
HBM Partners AG is a Swiss venture capital firm founded in 2001, headquartered in Zurich, Switzerland. The firm manages over USD 2.1 billion in assets under management (AUM) and has established itself as a key player in the healthcare investment space. HBM Partners focuses on venture, growth, and buy-out financings of private companies, as well as investments in public companies within the biopharma, medtech, diagnostics, and healthcare sectors.
With a strong operational presence in Europe and North America, HBM Partners also explores investment opportunities in emerging markets, including India and China. The firm is regulated by the Swiss Financial Market Supervisory Authority (FINMA) and advises on various specialized public and private equity investment funds. HBM Partners has achieved notable milestones, including over 100 investments and more than 60 successful exits through trade sales and IPOs.
HBM Partners AG invests primarily in the biopharma, medtech, diagnostics, and healthcare sectors. The firm engages in venture, growth, and buy-out financings, with investment amounts typically ranging from USD 5 million to 50 million. Their investment strategy emphasizes supporting the growth of portfolio companies through various stages of development, particularly in later-stage product and drug development.
The firm has a clear preference for later-stage companies, which allows them to leverage their extensive network and expertise in the healthcare sector. HBM Partners focuses on both private and public investments, aiming to facilitate access to capital for their portfolio companies. Their geographic focus includes North America and Europe, with additional interests in emerging markets like India and China, reflecting a global investment strategy.
HBM Partners AG has a diverse portfolio comprising over 100 companies, with a strong emphasis on biopharma, medical devices, and diagnostics. The firm has successfully executed more than 60 trade sales and IPOs, showcasing its ability to identify and nurture high-potential investments. The portfolio includes companies that have made significant advancements in their respective fields, contributing to the overall growth of the healthcare sector.
While specific current or notable portfolio companies were not detailed in the provided content, the firm's global diversification spans Western Europe, the United States, India, and China. This broad reach allows HBM Partners to tap into various markets and trends, enhancing the potential for successful exits and returns on investment.
Francesco D’Amico, Chairman - Francesco has extensive experience in healthcare investments and has been instrumental in guiding HBM Partners' strategic direction since its inception.
Didier de Montmollin, Board Member - Didier brings a wealth of knowledge in investment management and has played a key role in overseeing the firm's investment strategies.
Dr. Ulrich Geilinger, Board Member - Dr. Geilinger has a strong background in biopharma and healthcare, contributing valuable insights into the firm's investment decisions.
To pitch HBM Partners, startups should visit their website at hbmpartners.com for specific guidelines. The firm prefers detailed decks that outline the business model, market opportunity, and financial projections. While warm introductions are beneficial, they are not strictly necessary.
Response times may vary, but founders can expect to hear back within a few weeks after submission. It is advisable to ensure that all relevant information is included in the initial pitch to facilitate a timely review.
As of March 2026, HBM Partners AG has successfully completed over 100 investments, resulting in more than 60 trade sales and IPOs. The firm continues to actively seek new investment opportunities within the healthcare sector, focusing on later-stage companies that demonstrate significant growth potential.
Recent activities include ongoing investments in biopharma and medtech companies, with check sizes typically ranging from USD 10 million to 50 million. HBM Partners remains committed to supporting its portfolio companies through various stages of development, leveraging its extensive network and expertise.
What are HBM Partners' investment criteria?
HBM Partners focuses on the biopharma, medtech, diagnostics, and healthcare sectors, investing in companies at various stages, primarily later-stage. They typically invest between USD 5 million and 50 million.
How can startups apply or pitch to HBM Partners?
Startups interested in pitching to HBM Partners can visit their website at hbmpartners.com for more information on the application process.
What makes HBM Partners different from other venture capital firms?
HBM Partners is unique due to its focus on healthcare investments and its regulatory status as a FINMA-regulated entity. They also operate as a publicly traded investment company, providing liquidity for investors.
What is HBM Partners' geographic scope?
The firm primarily invests in North America and Europe, while also exploring opportunities in emerging markets such as India and China.
What is HBM Partners' post-investment involvement with portfolio companies?
HBM Partners adds value to its portfolio companies by providing strategic guidance, operational support, and facilitating access to capital through both private and public markets.
What is the typical check size for HBM Partners?
HBM Partners typically invests between USD 5 million and 50 million in their portfolio companies, focusing on substantial growth potential.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.